Monday morning at the ADA's 72nd Scientific Sessions featured the National Scientific & Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture. This year's recipient of the Outstanding Scientific Achievement Award was David Altshuler, MD, PhD, Professor of Medicine and Genetics at Harvard Medical School and Massachusetts General Hospital, Boston, for his work on genetic-based research regarding the inherited basis of type 2 diabetes, cholesterol levels, myocardial infarction, and a number of other conditions.
Monday morning at the ADA’s 72nd Scientific Sessions featured the National Scientific & Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture. This year’s recipient of the Outstanding Scientific Achievement Award was David Altshuler, MD, PhD, Professor of Medicine and Genetics at Harvard Medical School and Massachusetts General Hospital, Boston, for his work on genetic-based research regarding the inherited basis of type 2 diabetes, cholesterol levels, myocardial infarction, and a number of other conditions. Dr. Altshuler’s analysis included information from the Human Genome Project, population genetics, epidemiologic research, and clinical medicine.
Through their research analysis, Dr. Altshuler and his colleagues have been able to identify 50 novel regions of the human genome containing genes that influence the risk for type 2 diabetes, as well as for the risk of hyperglycemia, myocardial infarction, and dyslipiemia. The research team uses next-generation genome sequencing technologies in order to identify the pathophysiologic role of these novel genetic risk factors in greater detail. Their goal is to use this information to in order to identify new targets for the prevention and treatment of type 2 diabetes. Additionally, Dr. Altshuler and his colleagues are performing sequencing studies among various ethnic groups to better understand the disparities and genetic variants in different human populations.
Dr. Altshuler had an opportunity to discuss his ongoing research—which involves the genomes of 10,000 or more people—when he received his award on Monday morning. He began by crediting his colleagues and fellow researchers, saying that “science is a team sport, and I can’t imagine a better team to work with.” He then explained that there were 3 reasons he decided to become a geneticist after receiving his MD in endocrinology:
1) Important aspects of diabetes remain unidentified
2) These aspects limit and impede efforts to treat diabetes
3) We need more powerful methods to treat root causes in patients
Dr. Altshuler went on to briefly discuss high-level findings of his studies and mentioned a few ongoing genetic research studies that he is helping to spearhead, such as the SIGMA study, which aims to map out the genes of 9000 patients of Mexican descent.
But, after detailing the ongoing studies, Dr. Altshuler asked the audience, even if we are able to determine which genes play a role in diabetes, what do we want to know? “Some focus on prediction and personalized medicine,” said Dr. Altshuler. “I am less excited about this aspect and more interested in how this data will lead to better understanding and treatment [of diabetes].”
Dr. Atlshuler ended by saying that, although “99% of the genes in this audience” have been mapped, there still remains the issue of determining the purpose of many of these genes. Not knowing the purpose of a majority of these thousands of genes leaves “very few clues” as to where to look next. However, the lowest hanging fruit for progress, said Dr. Altshuler, is in instances where biological and genetics converge.
Here are some of the other awards that were given out at the ceremony.
Rachmiel Levine Award for Service
Geralyn R. Spollett, MSN, ANP-CS, CDE
Banting Medal for Service
Vivian Fonseca, MD
Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes
Pierre J. Lefebvre, MD, PhD
Albert Renold Award for the Distinguished Service in the Training of Diabetes Research Scientists
George S. Eisenbarth, MD, PhD
Kelly West Award for Outstanding Achievement in Epidemiology
Knut Borch-Johnsen, MD, PhD
Outstanding Physician Clinician in Diabetes Award
Georgeanna J. Klingensmith, MD
Outstanding Educator in Diabetes Award
Robin Nwankwo, MPH, RD
Outstanding Discovery Award
Samuel Rahbar, MD, PhD
Banting Medal for Scientific Achievement
Bruce M. Spiegelman, PhD
For more information on the recipients of these awards, please visit the American Diabetes Association’s website.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More